



中國抗體製藥有限公司
SinoMab BioScience Limited

SinoMab Awarded “Most Outstanding Biopharmaceutical Company of the Year”

[26 May 2021, Hong Kong] **SinoMab BioScience Limited** (“**SinoMab**” or the “**Company**”, stock code: **3681.HK**), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases, has been invited to “Hong Kong’s Most Outstanding Business Awards 2021” organised by local business media platform CorpHub and granted the “Most Outstanding Biopharmaceutical Company of the Year”, which reinforces its leadership as the first Hong Kong-based listed biopharmaceutical company.

As of now, SinoMab has successfully established a plentiful product pipeline targeting various indications such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and asthma. SM03, the Company’s flagship product for the treatment of RA, has been the first among all to enter phase-III clinical trial. The Company plans to file Biologics Licence Application (BLA) with the National Medical Products Administration (NMPA) of China as soon as the second half of 2021 and commercialise SM03 by the end of 2021 at the earliest. Also, key product SN1011, a third-generation covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, is currently in Phase I clinical trials in China and Australia respectively in a satisfying process.

The orderly research and development (R&D) of various products are backed by SinoMab’s full-spectrum platform across the industry chain, covering target identification, drug candidate development, pre-clinical research, clinical trials, clinical production, quality control, quality assurance, regulatory approval up to commercial-scale production, to which only a few premium biopharmaceutical companies in the Greater China region are comparable.

Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab, said, “The honour of the ‘Most Outstanding Biopharmaceutical Company of the Year’ is not only a recognition for SinoMab’s abiding endeavours but also a motivation for continuing our outstanding R&D. Going forward, leveraging the position as a Hong Kong-based full-spectrum biopharmaceutical company, we will strengthen our global presence, rapidly enhance our product pipeline and push forward with commercialisation, to discover and develop more novel drugs for the treatment of immunological diseases, thus advancing the medical industry together with all parties for the well-being of patients and society.”



Jason Hua, Chief Financial Officer of SinoMab (right), received the award

About Hong Kong’s Most Outstanding Business Awards

Since 2018, Hong Kong business media platform CorpHub has been annually hosting “Hong Kong’s Most Outstanding Business Awards”, aiming to appreciate enterprises with excellent contribution and achievements in Hong Kong and Asia. This year’s awardees span about 40 professional sectors, meticulously picked based on 4 criteria, namely (i) enterprise management and governance; (ii) financial performance and market competitiveness; (iii) innovation of products and amenities; and (iv) corporate social responsibility.

About SinoMab BioScience Limited

SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: **3681.HK**) is dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognised as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis, systemic lupus erythematosus, non-Hodgkin's lymphoma, asthma, and other diseases with major unmet clinical needs.

This press release is issued by Porda Havas International Finance Communications Group for and on behalf of **SinoMab BioScience Limited**. For further information, please contact:

Porda Havas International Finance Communications Group

Mr. Bunny Lee	+852 3150 6707	bunny.lee@pordahavas.com
Ms. Angela Shi	+852 3150 6778	angela.shi@pordahavas.com